Lipocine Inc. (NASDAQ: LPCN) Stock Information | RedChip

Lipocine Inc. (NASDAQ: LPCN) Listen to this Section


$3.65
-0.0100 ( -0.27% ) 45.1K

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

Market Data


Open


$3.65

Previous close


$3.66

Volume


45.1K

Market cap


$19.79M

Day range


$3.60 - $3.79

52 week range


$2.31 - $11.79

Insider Ownership Transactions

Total Amount Purchased: -14,704.00 | $ -53,669.60

Date Type Amount Purchased Purchaser
2024-06-07 Sale -1764.00 Fink Jeffrey Arvin
2024-06-07 Sale -1764.00 Higuchi John W.
2024-06-07 Sale -1764.00 Jene Jill M.
2024-06-07 Sale -1764.00 Ono Richard Dana
2024-06-07 Sale -1764.00 Papapetropoulos Spyros
2024-03-12 Sale -991.00 Fogarty Krista
2024-03-12 Sale -4893.00 Patel Mahesh V.

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 15 Aug 08, 2024
10-q Quarterly Reports 67 Aug 08, 2024
8-k/a 8K-related 14 Aug 07, 2024
8-k 8K-related 14 Jun 25, 2024
8-k 8K-related 41 Jun 10, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.